Physician profile
Sonia Mathew
NPI 1376809699
$3,313.90
in general payments reported to CMS, 2019-2025
24 companies · $431 in 2025
The $431 reported for 2025 was more than what 92% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $719 · 2020: $89.78 · 2021: $470 · 2022: $830 · 2023: $481 · 2024: $292 · 2025: $431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,205.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $436.70 | 2019-2025 | Spinraza, Spinraza |
| Biomerieux INC | $326.58 | 2023-2025 | Biofire Spotfire Respiratory (R) Panel, Filmarray Torch Module |
| Regeneron Healthcare Solutions, INC. | $241.08 | 2021-2022 | |
| Glaxosmithkline, LLC. | $236.68 | 2023-2025 | Benlysta, Bexsero |
| Astrazeneca Pharmaceuticals Lp | $234.71 | 2021-2022 | |
| Travere Therapeutics, INC. | $224.30 | 2019-2022 | |
| Genzyme Corporation | $219.62 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $217.38 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $184.76 | 2021-2022 | |
| Lnhc, INC | $124.69 | 2025 | Zelsuvmi |
| Rhythm Pharmaceuticals, INC. | $111.65 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $105.38 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $96.94 | 2022 | |
| Sobi, INC | $89.91 | 2019 | |
| Novartis Pharmaceuticals Corporation | $89.78 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $87.18 | 2022-2023 | Immunocap |
| Mirum Pharmaceuticals, INC. | $85.86 | 2023 | Livmarli |
| Gilead Sciences, INC. | $61.00 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.21 | 2022 | |
| Abbvie INC. | $20.52 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $19.36 | 2025 | Zoryve |
| Sanofi Pasteur INC. | $18.25 | 2025 | |
| Tris Pharma INC | $16.20 | 2023 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $14.16 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonia Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.